

EXTRAGASTRIC MANIFESTATIONS OF HELICOBACTER PYLORI INFECTION

D. ORGA-DUMITRIU¹, C. TĂNĂSESCU², A. TEODORU³, DORA TEODORU⁴

^{1,2,3,4} "Lucian Blaga" University of Sibiu

Keywords:

Helicobacter pylori, infection, extragastric manifestations

Abstract: Implications of *Helicobacter pylori* infection in esogastroduodenal pathology are well known. A lot of studies focused on the pathological properties of this bacteria have suggested its involvement in the ethiological determinism of some extragastric diseases, far beyond gastric colonization. For some of them, the role of *Helicobacter pylori* has been already proved (idiopathic thrombocytopenic purpura, iron deficiency anemia), but its etiopathogenic impact is still unclear with reference to other morbid entities (ischemic heart disease, diabetes mellitus, Alzheimer's disease).

Cuvinte cheie:

Helicobacter pylori, infecție, manifestări extragastrice

Rezumat: Implicațiile infecției cu *Helicobacter pylori* (Hp) în patologia esogastroduodenală sunt binecunoscute. Numeroasele studii care s-au concentrat asupra valențelor patologice ale bacteriei au sugerat intervenția acesteia în etiopatogenia unor boli extragastrice, depășind cu mult zona anatomică antrală de colonizare gastrică. Pentru unele patologii, determinismul infecției cu Hp este cert dovedit (purpura trombocitopenică autoimună, anemia feriprivă), impactul etiopatogenic fiind încă neclar cu referire la alte entități morbide (boala cardiacă ischemică, diabetul zaharat, boala Alzheimer)

SCIENTIFIC ARTICLE OF BIBLIOGRAPHIC SYNTHESIS

Since the first report of Warren and Marshall in 1983 regarding the *Helicobacter pylori*, the authors suspected this bacteria to be implicated in some gastroduodenal diseases. Thousands of studies dissected with fervour this interrelation, unequivocally demonstrating the central role of Hp in the genesis of gastric and duodenal ulcer (1,2,3), gastritis (4) and stomach cancer (5,6). Meanwhile, a series of observations have expanded the Hp pathophysiological impact to the esogastroduodenal region until absolutely unexpected areas, such as cardiovascular and neurological pathology or diabetes mellitus. Extragastric manifestations of *Helicobacter pylori* infection continues to capture the attention of researchers worldwide, many studies have been published in recent years.

Cardiovascular pathology. The role of inflammation in the pathogenesis of coronary artery disease, via atherosclerosis, was clearly stated (7,8). It has been demonstrated that the infection with *Helicobacter pylori* is associated with an inflammatory response that includes increases of TNF- α , interleukin 1 β , reactive C protein, intercellular adhesion molecules (ICAM-1) and vascular adhesion molecules (VCAM-1)(9,10,11). Given the long persistence of bacteria in gastric mucosa, often for life, we can accept the idea that the subsequent inflammatory response has a chronic nature, though of low intensity, as demonstrated by Graham in 1989 (12). Systemic inflammatory response and ischemic heart disease would be associated mainly with strains expressing cagA virulence factor (13). Other recent studies reached to a similar conclusion (14, 15). Another mechanism for promoting ischemic heart disease would be the interaction between Hp and von Willebrand factor which would determine, by binding to glycoprotein 1b, platelet aggregation and

thrombosis (16).

Diabetes mellitus. Recently (2009) was published the first study to demonstrate the presence of insulin secretory dysfunction in patients infected with cagA+ strains (17). Other previous studies, based on epidemiological data, showed association of *Helicobacter pylori* infection with increased incidence of diabetes mellitus (18). On the other hand, Ojetti et al. showed a growth rate of reinfection in diabetic patients, suggesting a reciprocal determinism (19).

Hematological pathology

Idiopathic thrombocytopenic purpura (ITP). *Helicobacter pylori* is a known cause of idiopathic thrombocytopenic purpura (20,21). Pathogenetic mechanism appears to be the existence of a structural similarity between a platelet component, that is a receptor for von Willebrand factor, and vacuolated cytotoxin secreted by cagA+ strains, which would trigger an immune cross response (22). Eradication of bacteria in patients with ITP would significantly increase the response to treatment (23).

Iron deficiency anemia. *Helicobacter pylori* association with iron deficiency anemia has as the main substrate obvious or occult bleeding due to the induced gastroduodenal pathologies (ulcers, ulcerations, cancer). Low ferritin and ascorbic acid levels in patients infected with cagA+ strains (24) and decrease iron absorption in patients with chronic atrophic gastritis are incriminated too.

Dermatological pathology. Recent studies suggest that Hp may play a role in the pathogenesis of various skin diseases, particularly chronic urticaria. The intervention of bacteria would be not as a trigger, but as a factor which facilitates the exacerbations of this pathology (25). As for other dermatological diseases, such as alopecia areata and Behçet's

¹Corresponding Author: D. Orga-Dumitriu, Medicine Faculty "Victor Papilian" Sibiu, 2A, Lucian Blaga street, Sibiu, 550169, România, e-mail:; tel: +40744770905

Article received on 07.04.2011 and accepted for publication on 23.08.2011
ACTA MEDICA TRANSILVANICA December 2011; 2(4)223-225

CLINICAL ASPECTS

disease, involving *Helicobacter pylori* was not demonstrated (26, 27).

Ophthalmological pathology. Idiopathic central serous chorioretinopathy is more common in patients infected with Hp (28) and tend to have a higher incidence of remission after eradication of bacteria (29). It has been demonstrated (30) that patients with normal tension glaucoma have a higher prevalence of infection with *Helicobacter pylori*, indicating a possible role of bacteria in the promotion or evolution of this eye disease

Neurological pathology. A recent study (31) has shown increased levels of anti-Hp IgG in cerebrospinal fluid of patients with Alzheimer's disease. Eradication of bacteria has led to significant improvements in clinical manifestations (32). *Helicobacter pylori* appear to play a role in idiopathic Parkinsonism (33).

Obesity. It has been demonstrated (34) that the *Helicobacter pylori* eradication predisposes to obesity. Oxyntic gastric glands contain cells that regulate appetite through ghrelin pathway. This hormone has orexigen effect, stimulates gastric secretion and motility and inhibits secretion of leptin with anorexogenic role. Aggressive strains of Hp promote a potent gastric inflammatory response, followed by gastric atrophy, which decrease gastric and systemic ghrelin levels (35). The disappearance of the bacteria in the gastric mucosae upregulates GR ghrelin secreting cells, which makes it possible to promote appetite and weight gain.

Gynecologic pathology. There is evidence suggesting the involvement of *Helicobacter pylori* in various obstetrical and gynecological morbid circumstances, such as pre-eclampsia (36), hyperemesis gravidarum (37) or polycystic ovary syndrome (38).

Hepatobiliary pathology. Infection with *Helicobacter pylori* is accepted as a precipitating factor in gallstone formation and recent studies (39,40) showed the presence of bacteria in the hepatobiliary system. Ki et al conducted a study (41) that demonstrates that *Helicobacter pylori* association with increased levels of TGF- β 1 may accelerate liver fibrosis by proinflammatory signaling pathways from hepatic stellate cells.

Pulmonary pathology. Researchers have noticed recently a positive correlation between the seroprevalence of Hp and lung neoplasm and propose as pathophysiological mechanism the increased levels of gastric, whose role in promoting cell proliferation and angiogenesis is well known; these effects would exercise on bronchial epithelium too (42,43). It was also published a study (44) focused on a case of sarcoidosis cured after *Helicobacter pylori* eradication..

CONCLUSIONS

In conclusion, we can say that, currently, the involvement of Hp has been clearly proven for some extragastric pathologies (idiopathic thrombocytopenic purpura, iron deficiency anemia), but questions remain concerning the role of bacteria in other diseases, which leaves open area of research aimed to clarify the unknown valences of *Helicobacter pylori*.

BIBLIOGRAPHY

1. Marshall BJ, McGeachie DB, Rogers PA, Glancy RJ. Pyloric *Campylobacter* infection and gastroduodenal disease. *Med J Aust* 1985; 142:439.
2. Nomura A, Stemmermann GN, Chyou PH, et al. *Helicobacter pylori* infection and the risk for duodenal and gastric ulceration. *Ann Intern Med* 1994; 120:977.
3. Hopkins RJ, Girardi LS, Turney EA. Relationship between *Helicobacter pylori* eradication and reduced duodenal and gastric ulcer recurrence: a review. *Gastroenterology* 1996; 110:1244.
4. Calam J, *Helicobacter pylori*, *Eur J Clin Invest*, 1994 Aug 24(8):501-10
5. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. *Lancet* 1975;2:58-60
6. Sipponen P, Kekki M, Haapakoski J, Ihmaki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. *Int J Cancer* 1985;35:173-177
7. Rader DJ, Inflammatory markers of coronary risk, *N Engl J Med*, 343: 1179-1182;
8. Libby P, Egan D, Skarlatos S, Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research, *Circulation*,1997, 96: 4095-4103;
9. Mc Gowan CC, Cover LL, Blaser MJ, *Helicobacter pylori* and gastric acid: biological and therapeutic implications, *Gastroenterology*, 1996, 110: 926-38;
10. Khaled MA, Mahalanabis D, Higher Serum Tumor Necrosis Factor in H. Pylori Infected Humans with Higher Body Mass Index, *The FASEB J*, 14: A248;
11. Siddiqui NR, Garvey WT, Khaled MA, *Helicobacter pylori* induces higher C-Reactive Protein in Obese African Americans, *Artery Res*, 2009, 3: 39-42;
12. Graham DY, *Campylobacter pylori* and peptic ulcer disease, *Gastroenterology*, 1989, 96: 615-625;
13. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarri A et al., Association of Virulent *Helicobacter Pylori* Strains with Ischemic Heart Disease, *Circulation*, 1998, 97: 1675-1679;
14. Niccoli G, Franceschi F, Cosentino N, Guipponi B, De Marco G, Merra G et al., Coronary atherosclerotic burden in patients with infection by CagA-positive strains of *Helicobacter pylori*, *Coron Artery Dis* 2010; 21: 217-21;
15. Huang B, Chen Y, Xie Q, Lin G, Wu Y, Feng Y et al., Cag-A positive *Helicobacter pylori* strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. *Dig Dis Sci* 2011; 56:109-14;
16. Fagoonne S, De Angelis C, Elia C, Silvano S, Oliaro E, Rizzetto M, Pelicano R, Potential link between *Helicobacter pylori* and inchemic heart disease: does the bacterium elicit thrombosis? *Minerva Med* 2010; 101: 121-5;
17. Afzalur F, Mark B, Shafique A, Garvey T et al., *Helicobacter pylori* Infection and Inflammation: Implications for Pathophysiology of Diabetes Mellitus and Coronary Heart Disease, *J Life Sci*, 2009; 1 (1): 45-50;
18. Ataseven H, Demir M, Gen R, Effect of sequential treatment as a first-line therapy for *Helicobacter pylori* eradication in patients with diabetes mellitus, *South Med J* 2010; 103:988-92;
19. Ojetti V, Pellicano R, Fagoonee S, Migneco A, Berrutti M, *Helicobacter pylori* infection and diabetes, *Minerva Med* 2010; 101: 115-9;
20. Veneri D, Bonani A, Franchini M, Fedrizzi A, Idiopathic thrombocytopenia and *Helicobacter pylori* infection, *Trop Gastroenterol* 2010; 31:34-6;
21. Godeau B, Michel M, Treatment of chronic immune thrombocytopenic purpura in adults. *Ann Hematol* 2010; Apr 14 (Epub ahead of print)
22. Scandellari R, Allemand E, Vettore S, Plebani M, Randi ML, Platelet response to *Helicobacter pylori* eradication therapy in adult chronic idiopathic thrombocytopenic purpura seems to be related to the presence of anticytotoxin-associated gene A antibodies, *Blood Coagul*

CLINICAL ASPECTS

- Fibrinolysis 2009;20:108-13;
23. Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y et al, Platelet count response to Helicobacter pylori treatment in patients with immune thrombocytopenic purpura with and without Helicobacter pylori infection: a systematic review. *Haematologica* 2009; 94:850-6;
 24. Muhsen K, Barak M, Shifnadel L, Nir A, Bassal R, Cohen D, Helicobacter pylori infection is associated with low serum ferritin levels in Israeli Arab children: a seroepidemiologic study, *J Pediatr Gastroenterol Nutr* 2009; 49: 262-4;
 25. Abdou AG, Elshayeb EI, Farag AG, Elnaidany NF, Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies, *Int J Dermatol* 2009; 48:464-9;
 26. Abdel-Hafez HZ, Mahran AM, Hofny ER, Rashed H, Is Helicobacter pylori infection associated with alopecia areata? *J Cosmet Dermatol* 2009; 8:52-5;
 27. Cakmak SK, Cakmak A, Gul U, Sulaimanov M, Bingol P, Upper gastrointestinal abnormalities and Helicobacter pylori in Behcet disease 2009; 48:1174-6;
 28. Misiuk-Hjlo M, Michalowska M, Turno-Krecika A, Helicobacter pylori – a risk factor for the development of the central serous chorioretinopathy, *Klin Oczna* 2009; 111:30-2;
 29. Rahbani-Nobar MB, Javadzadeh A, Rafeey M, The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy, *Mol Vis* 2010;17:99-103;
 30. Kim JM, Kim SH, Park KH, Han SY, Shim HS, Investigation of the association between Helicobacter pylori infection and normal tension glaucoma, *Invest Ophthalmol Vis Sci* 2010; 52:665-8;
 31. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N. et al, Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease, *Int J Neurosci* 2009; 119:765-77;
 32. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N. et al, Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease, *J Neurol* 2009; 256:758-67;
 33. Dobbs SM, Dobbs RJ, Weller C, Charlett A, Bjarnason IT, Lawson AJ, Differential effect of Helicobacter pylori eradication on time-trends in brady/hypokinesia and rigidity in idiopathic parkinsonism, *Helicobacter* 2010; 15:279-94;
 34. Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Extragastric Manifestations of Helicobacter pylori Infection, *Helicobacter* 2010; 15 (Suppl):60-68;
 35. Kawashima J, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S et al., Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis, *J Gastroenterol* 2009; 44:1046-54;
 36. Aksoy H, Ozkan A, Aktas F, Borekci B, Helicobacter pylori seropositivity and its relationship with serum malondialdehyde and lipid profile in preeclampsia, *J Clin Lab Anal* 2009; 23:219-22;
 37. Sandven I, Abdelnoor M, Nesheim BI, Melby KK, Helicobacter pylori infection and hyperemesis gravidarum: a systematic review and meta-analysis of case-control studies, *Acta Obstet Gynecol Scand* 2009; 88:1190-200;
 38. Yavasoglu I, Kucuk M, Cidag B, Arslan E, Gok M, Kafkas S, A novel association between polycystic ovary syndrome and Helicobacter pylori, *Am J Med Sci* 2009; 338:174-7;
 39. Lee JW, Lee DH, Lee JI et al, Identification of Helicobacter pylori in gallstone, bile and other hepatobiliary tissues of patients with cholecystitis, *Gut Liver* 2010; 4:60-7;
 40. Isaeva GSh, Abuzarova ER, Valeeva IuV, Pozdeev OK, Muravaeva EV, Helicobacter pylori in patients with disorders of hepatobiliary system, *Zh Mikrobiol Epidemiol Immunobiol* 2009; 2:96-101;
 41. Ki MR, Goo MJ, Park MJ, Hong IH, Ji AR, Han SY et al, Helicobacter pylori accelerates hepatic fibrosis by sensitizing transforming growth factor-beta1-induced inflammatory signaling, *Lab Invest* 2010; 90:1507-16;
 42. Hidekazu S, Franceschi F, Nishizawa T, Gasbarrini A, Extragastric Manifestations of Helicobacter pylori Infection, *Helicobacter* 2011; 16 (Suppl):65-69;
 43. Zhuo WL, Zhu B, Xiang ZL, Zhuo XL, Cai L, Chen ZT, Assessment of the relationship between Helicobacter pylori and lung cancer: a meta-analysis, *Arch Med Res* 2009; 40:406-10;
 44. Riviere F, Roux X, Mechai F, Imbert P, Rapp C, Cured pulmonary sarcoidosis and Helicobacter pylori eradication: cause or coincidence? *Presse Med* 2011;40:765-7.